Zobrazeno 1 - 10
of 18
pro vyhledávání: ''
Autor:
Linda Vainikka, Sten Wingren, L E Rutqvist, Olle Stål, Lambert Skoog, Pia Wegman, Bo Nordenskjöld
Publikováno v:
Breast Cancer Research
Background Tamoxifen is widely used as endocrine therapy for oestrogen-receptor-positive breast cancer. However, many of these patients experience recurrence despite tamoxifen therapy by incompletely understood mechanisms. In the present report we pr
Autor:
Hanna Birke, Anthony Howell, Adam R. Brentnall, Stephen W. Duffy, Jennifer Stone, Ruth Warren, Jack Cuzick, Elizabeth Pinney, Jane Warwick
Publikováno v:
Breast Cancer Research : BCR
Introduction Mammographic density is well-established as a risk factor for breast cancer, however, adjustment for age and body mass index (BMI) is vital to its clinical interpretation when assessing individual risk. In this paper we develop a model t
Autor:
Timothy R. Rebbeck, Martin S. Tallman, Richard Aplenc, Robert Gray, Angela DeMichele, Phyllis A. Gimotty, Michelle Horn, Priya P Gor, William P. Vaughan, H. Irene Su
Publikováno v:
Gor, Priya P; Su, H Irene; Gray, Robert J; Gimotty, Phyllis A; Horn, Michelle; Aplenc, Richard; et al.(2010). Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Research, 12(3), R26. doi: http://dx.doi.org/10.1186/bcr2570. Retrieved from: http://www.escholarship.org/uc/item/8j08f5kc
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Introduction Cyclophosphamide-based adjuvant chemotherapy is a mainstay of treatment for women with node-positive breast cancer, but is not universally effective in preventing recurrence. Pharmacogenetic variability in drug metabolism is one possible
Autor:
Maria García-Aranda, Teresa Téllez, Maria Luisa Hortas, Alfonso Serrano, Maximino Redondo, Maria J. Roldan, Martin E. Gleave, Miguel Morell
Publikováno v:
Breast Cancer Research : BCR
Introduction Overexpression of the apoptosis-related protein clusterin is associated with breast cancer development and tumor progression. We describe the use of clusterin-specific antisense oligonucleotides and antibodies to sensitize breast carcino
Autor:
Zoann Nugent, Tarek Bader, Anuraag Shrivastav, Peter H. Watson, Mary Christine Bruce, Leigh C. Murphy, Srinivas V Seekallu, Danira Jaksic, Carla Penner
Publikováno v:
Breast Cancer Research : BCR
Introduction A phosphorylation score for estrogen receptor-alpha (ERα), called P7 score, was shown previously to be an independent prognostic factor in breast cancer patients treated with tamoxifen. Since mechanistic target of rapamycin (mTOR) activ
Autor:
Basileios Venizelos, V. Zobolas, J. Papadiamantis, Helen Gogas, Zoh Antonopoulou, Dimitrios Koukouras, Grigorios Xepapadakis, Urania Dafni, John Misitzis, Evagelos Tzoracoleftherakis, Christos Markopoulos
Publikováno v:
Breast Cancer Research : BCR
Introduction Extended adjuvant endocrine therapy for breast cancer with aromatase inhibitors may potentially alter the lipid profile of postmenopausal patients and thus increase the risk of developing cardiovascular disease. In this study, a subproto
Autor:
Kathleen C. Flanders, JoAnne Zujewski, Anika Vaughn-Cooke, Lalage M. Wakefield, Michael Eckhaus, Ronald A. Lubet
Publikováno v:
Breast Cancer Research
Using a carcinogen-initiated rat model of mammary tumorigenesis, we tested the hypothesis that transforming growth factor (TGF)-betas are useful biomarkers of chemopreventive efficacy in the breast. The chemopreventive agents tested were tamoxifen an
Autor:
Carole Chaboteaux, Guy Laurent, Hugues Duvillier, Jean-Jacques Body, Fabrice Journe, Nicolas Magne
Publikováno v:
Breast cancer research, 8 (1
Breast Cancer Research
Breast Cancer Research
Bisphosphonates are inhibitors of osteoclast-mediated tumor-stimulated osteolysis, and they have become standard therapy for the management of bone metastases from breast cancer. These drugs can also directly induce growth inhibition and apoptosis of
Autor:
John F.R. Robertson, Julia Margaret Wendy Gee, Denise Barrow, Robert Ian Nicholson, Ian O. Ellis, Iain Robert Hutcheson, Janice Mary Knowlden, Stephen Edward Hiscox
Publikováno v:
Breast cancer research : BCR
Introduction\ud Resistance to anti-epidermal growth factor receptor (anti-EGFR) therapies is an emerging clinical problem. The efficacy of anti-EGFR therapies can be influenced by the presence of heregulins (HRGs), which can bind erbB3/4 receptors an
Autor:
Li Lu, Robert Bagdasaryan, A. Raymond Frackelton, Dennis C. Sgroi, Pamela A. Davol, Laurie J. Hafer
Publikováno v:
Breast Cancer Research
Introduction Shc adapter proteins are secondary messenger proteins involved in various cellular pathways, including those mediating receptor tyrosine kinase signaling and apoptosis in response to stress. We have previously reported that high levels o